Patent SG-11201809473Q-A (SG)
Title: Humanized anti-basigin antibodies and the use thereof
Inventor: CHEN ZHINAN
IPC: C07K16/42
Filed: 2017-05-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 31101H11111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/186182 Al 02 November 2017 (02.11.2017) W I PO I PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 16/42 (2006.01) A61P 35/00 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 39/395 (2006.01) A61P 33/06 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (21) International Application Number: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, PCT/CN2017/082713 KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: Published: 02 May 2017 (02.05.2017) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201610285139.4 29 April 2016 (29.04.2016) CN (71) Applicant: FOURTH MILITARY MEDICAL UNIVERSITY [CN/CN]; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). (72) Inventors: CHEN, Zhinan; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). ZHU, Ping; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). HUANG, Wan; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). ZHANG, Zheng; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). ZHANG, Yang; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). ZHANG, Mengyao; No.169 West Changle Road, Xi'an, Shaanxi = 710032 (CN). BIAN, Huijie; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). JIANG, Jianli; No.169 West Changle Road, Xi'an, Shaanxi 710032 (CN). Agent: JUN HE LAW OFFICES; 20/F, China Resources (74) Building, 8 Jianguomenbei Avenue, Beijing 100005 (CN). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (84) 1-1 ei Pt (54) Title: HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE THEREOF 1-1 (57) : Provided herein is a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy *t chain variable region(V H) comprising an amino acid sequence of SEQ ID NO:1, optionally further comprises light chain variable region 1-1 ---- (V L) comprising an amino acid sequence of SEQ ID NO: 2. Also provided a composition comprising the humanized anti-BASIGIN IN antibody or antigen binding fragment thereof, an isolated nucleic acid sequence encoding the humanized anti-BASIGIN antibody or 0 antigen binding fragment thereof, a vector comprising the nucleic acid, a host cell comprising the vector, and use of the humanized ei anti-BASIGIN antibody or antigen binding fragment thereof. 0